Format
Sort by

Send to

Choose Destination

Links from Nucleotide

Items: 9

1.

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, Scarfò L, Davis Z, Yan XJ, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, Moreno D, Van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc MP, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Blood. 2015 Jan 29;125(5):856-9. doi: 10.1182/blood-2014-09-600874. Epub 2014 Dec 17.

2.

IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia.

Cahill N, Sutton LA, Jansson M, Murray F, Mansouri L, Gunnarsson R, Ryan F, Smedby KE, Geisler C, Juliusson G, Rosenquist R.

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):201-6. doi: 10.1016/j.clml.2012.01.009. Epub 2012 Mar 29.

PMID:
22464020
3.

Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia.

Ghia EM, Widhopf GF 2nd, Rassenti LZ, Kipps TJ.

J Immunol. 2011 Jun 1;186(11):6338-44. doi: 10.4049/jimmunol.0902875. Epub 2011 Apr 27.

4.

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, Catovsky D; Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute.

Haematologica. 2010 Oct;95(10):1705-12. doi: 10.3324/haematol.2010.025338. Epub 2010 May 29.

5.

IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.

Abramenko I, Bilous N, Kryachok I, Filonenko I, Pilipenko G, Chumak A, Bazyka D, Bebeshko V.

Exp Oncol. 2007 Sep;29(3):226-30.

PMID:
18004251
6.

Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study.

Bomben R, Dal Bo M, Capello D, Benedetti D, Marconi D, Zucchetto A, Forconi F, Maffei R, Ghia EM, Laurenti L, Bulian P, Del Principe MI, Palermo G, Thorsélius M, Degan M, Campanini R, Guarini A, Del Poeta G, Rosenquist R, Efremov DG, Marasca R, Foà R, Gaidano G, Gattei V.

Blood. 2007 Apr 1;109(7):2989-98.

7.

Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene.

Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stella S, Guida G, Michel A, Crespo M, Laoutaris N, Montserrat E, Anagnostopoulos A, Dighiero G, Fassas A, Caligaris-Cappio F, Davi F.

Blood. 2005 Feb 15;105(4):1678-85. Epub 2004 Oct 5.

8.

The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.

Matsuda F, Ishii K, Bourvagnet P, Kuma Ki, Hayashida H, Miyata T, Honjo T.

J Exp Med. 1998 Dec 7;188(11):2151-62.

9.

The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops.

Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G.

J Mol Biol. 1992 Oct 5;227(3):776-98.

PMID:
1404388
Items per page

Supplemental Content

Write to the Help Desk